Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000256545 | SCV000324751 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-10-18 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000256545 | SCV000328081 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001019066 | SCV001180375 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-04-17 | criteria provided, single submitter | clinical testing | The p.K3083* pathogenic mutation (also known as c.9247A>T), located in coding exon 23 of the BRCA2 gene, results from an A to T substitution at nucleotide position 9247. This changes the amino acid from a lysine to a stop codon within coding exon 23. Same protein change has been reported in a Spanish breast cancer kindred (Duran M et al. Hum Mutat. 2003 Apr;21(4):448). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV001380998 | SCV001579246 | pathogenic | Hereditary breast ovarian cancer syndrome | 2020-02-02 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant has been observed in individual(s) with breast or ovarian cancer (PMID: 29446198). ClinVar contains an entry for this variant (Variation ID: 52783). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Lys3083*) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. |